Prognostic value of platelet volume indices in patients with resectable esophageal squamous cell carcinoma
YUE Xiang1, HUANG Hao2, WANG Wen3, TIAN Mang1
1. Department of Cardiothoracic Urology, the 987th Hospital of PLA Joint Logistics Support Force, Baoji 721000, China; 2. Department of Cardiothoracic Surgery, General Hospital of PLA Central Theater Command, Wuhan 430064, China; 3. School of Medicine of Yan’an University, Yan’an 716000, China
摘要目的 探讨术前血小板体积指数(PVI)对可切除食管鳞状细胞癌(ESCC)患者预后的评估价值。方法 回顾性分析2013-03至2023-06进行手术治疗的210例ESCC患者的临床资料,根据患者术前各项PVI指数的受试者工作特征曲线(ROC)获得截断值,Kaplan-Meier方法和COX模型分析了PVI对ESCC患者预后的影响。结果 随访5年,125例(59.52%)患者死亡,中位OS为15.0个月(范围3~60个月)。与存活组比较,死亡组血小板计数(PLT)[250.50(205.0,300.50) vs. 212.50(179.50,278.50),Z=-2.801,P=0.005]、血小板分布宽度(PDW)[12.90(11.80,15.80)FL vs. 11.30(10.40,14.95)FL,Z=-2.665,P=0.008]均有所升高(P＜0.05),PDW/PLT[12.90(11.80,15.80) vs. 11.30(10.20,15.05),Z=-6.719,P＜0.001]显著升高,平均血小板体积(MPV)/PLT[0.04(0.03,0.04) vs. 0.05(0.04,0.06),Z=-10.847,P＜0.001]显著降低。受试者工作特征曲线显示PLT、PDW、MPV/PLT、PDW/PLT都可以用于预测可切除ESCC患者的死亡风险(P＜0.05),但PLT、PDW的临床价值不高[曲线下面积(AUC)＜0.7];当MPV/PLT≥0.043或PDW/PLT≥60.230时,AUC值分别为0.771和0.802;当两者联合时,预测死亡风险的AUC值升高至0.929。相对MPV/PLT＞0.043、PDW/PLT≤60.230的患者,MPV/PLT≤0.043(Log-Rank=34.502,P＜0.001)、PDW/PLT＞60.230(Log-Rank=172.056,P＜0.001)的ESCC患者总生存期(OS)更短。经COX多因素模型分析,发现PDW/PLT＞60.230、MPV/PLT>0.043与ESCC患者术后死亡独立相关(P＜0.05)。结论 PVI是可切除ESCC患者术后的潜在预后指标,尤其是MPV/PLT和PDW/PLT联合检测的临床预后价值更理想。
Abstract：Objective To evaluate the prognostic value of platelet volume indices (PVI) in patients with resectable esophageal squamous cell carcinoma (ESCC). Methods Clinical data of 210 patients with ESCC who underwent surgery from March 2013 to June 2023 were retrospectively analyzed, and the cut-off values of PVI were obtained from the receiver operating characteristic curve (ROC), and the Kaplan-Meier method and COX model were used to analyze the effect of PVI index on the prognosis of ESCC patients. Results During a 5-year follow-up, 125 patients (59.52%) died, with a median OS of 15.0 months (range of 3-60 months). Compared with the survival group, platelet count (PLT) in the death group[250.50 (205.0, 300.50) vs. 212.50 (179.50, 278.50), Z=-2.801, P=0.005], platelet distribution width (PDW) in the death group[12.90 (11.80, 15.80) FL vs. 11.30 (10.40, 14.95) FL, Z=-2.665, P=0.008]increased (P＜0.05), PDW/PLT[12.90 (11.80, 15.80) vs. 11.30 (10.20, 15.05), Z=-6.719, P＜0.001]significantly increased, and the mean platelet volume (MPV) /PLT significantly decreased[0.04 (0.03, 0.04) vs. 0.05 (0.04, 0.06), Z=-10.847, P＜0.001]. The receiver operating characteristic curve showed that PLT, PDW, MPV/PLT and PDW/PLT could all be used to predict the mortality risk of patients with resectable ESCC, P＜0.05, but the clinical value of PLT and PDW was not high[area under the curve (AUC)＜0.7]; when MPV/PLT≥0.043 or PDW/ PLT≥60.230,the AUC values were 0.771 and 0.802, respectively, and when the two were combined, the AUC values for predicting mortality risk increased to 0.929.Compared with patients with MPV/PLT>0.043 and PDW/PLT≤60.230, the overall survival (OS) of ESCC patients with MPV/PLT≤0.043(Log-Rank=34.502,P＜0.001) and PDW/PLT＞60.230(Log-Rank=172.056,P＜0.001) was shorter. The COX multivariate model analysis showed that PDW/PLT＞60.230 and MPV/PLT＞0.043 were independently associated with postoperative mortality in ESCC patients (P＜0.05). Conclusions PVI is a potential prognostic indicator for resectable ESCC patients after surgery, especially the clinical prognostic value of combined detection of MPV/PLT and PDW/PLT is more ideal.
Yang W, Xing X, Yeung S J, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(1): e003497-e003507.
Li X, Zhao K, Lu Y, et al. Genetic analysis of platelet-related genes in hepatocellular carcinoma reveals a novel prognostic signature and determines PRKCD as the potential molecular bridge[J]. Biol Proced Online, 2022, 24(1): 22-44.
Zhang X, Qin Y Y, Chen M, et al.Combined use of mean platelet volume/platelet count ratio and platelet distribution width to distinguish between patients with nasopharyngeal carcinoma, those with benign tumors of the nasopharynx, and healthy subjects[J]. Cancer Manag Res, 2019, 11: 10375-10382.
[12]
Gozdas H T, Ince N. Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C[J]. Eur J Gastroenterol Hepatol, 2020, 32(4): 524-527.
[13]
Lin Y C, Jan H C, Ou H Y, et al. Low preoperative mean platelet volume/platelet count ratio indicates worse prognosis in non-metastatic renal cell carcinoma[J]. J Clin Med, 2021, 10(16): 3676-3687.
[14]
Feng J F, Sheng C, Zhao Q, et al. Prognostic value of mean platelet volume/platelet count ratio in patients with resectable esophageal squamous cell carcinoma: a retrospective study[J]. Peer J, 2019,7: e7246-e7260.
[15]
Su R, Zhu J, Wu S, et al. Prognostic significance of platelet (PLT) and platelet to mean platelet volume (PLT/MPV) ratio during apatinib second-line or late-line treatment in advanced esophageal squamous cell carcinoma patients[J]. Technol Cancer Res Treat, 2022, 21: 15330338211072974-15330338211072983.
[16]
Shen Y, Xu H, Guan Z, et al. Effect of rho GTPase activating protein 9 combined with preoperative ratio of platelet distribution width to platelet count on prognosis of patients with serous ovarian cancer[J]. Transl Cancer Res, 2021, 10(10): 4440-4453.
[17]
Takeuchi H, Abe M, Takumi Y, et al. The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer[J]. PLoS One, 2017, 12(12): e0189166-e0189176.
Kim H E, Park S Y, Kim H, et al. Prognostic effect of perineural invasion in surgically treated esophageal squamous cell carcinoma[J]. Thorac Cancer, 2021, 12(10): 1605-1612.
[21]
Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis[J]. J Hematol Oncol, 2021, 14(1): 173-189.
2024, Vol. 35 
